AKT1 and breast carcinoma: PARP inhibitors, PI3K/AKT/mTOR inhibitors, CDK4/6 inhibitors and HER2 TKIs emerged as potential targeted therapies of gBRCA-mutated, PIK3CA-mutated, ER + , and HER2 + subtypes of breast cancer, respectively.